Immunological Aspects of Mood Disorders: Interaction Between Cytokines and Intracellular Calcium Signaling

  • Ariyuki Kagaya
  • Shigeto Yamawaki
Conference paper


The immune system is one of the most important organs, discriminating “self” from “nonself” and protecting “self” from invasion by pathogens or from abnormal “self”. The organs of the peripheral immune system are the thymus, spleen, and lymph nodes. The available cells of the immune system include T cells, B cells, and natural killer (NK) cells. Immune responses are typically divided into two components: cellular immunity and hormonal activity by soluble substances such as cytokines. There is increasing evidence of communication among the immune system, the central nervous system (CNS), and the endocrine system at various levels (Jankovic 1994; Dunn 1995). Numerous studies have been published since the 1970s regarding the association between psychological phenomena and immune function. This area of these investigations is now characterized as “psychoneuroimmunology” (Irwin 1995), although there is not sufficient evidence to support interactions between psychological phenomena and immune function. Here we consider the pathophysiology of mood disorders in regard to immune function and demonstrate the importance of intracellular calcium (Ca2+) signaling as a possible factor that associates immune function with psychological phenomena.


Nitric Oxide Human Immunodeficiency Virus Natural Killer Depressed Patient Affective Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arthur CK, Ma DDF (1993) Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 89: 15–21PubMedCrossRefGoogle Scholar
  2. Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA (1988) Prevalence of psychiatric disorders among men infected with human immuno-deficiency virus. Arch Gen Psychiatry 45: 859–864PubMedCrossRefGoogle Scholar
  3. Bartrop RW, Luckhurst E, Lazarus L, Kikoh LG, Penny R (1977) Depressed lymphocyte function after bereavement. Lancet l (8016): 834–836Google Scholar
  4. Berk M, Bodemer W, van Oudenhove T, Butkow N (1995) The platelet intracellular calcium response to serotonin in augmented in bipolar manic and depressed patients. Human Psychopharmacol 10: 189–193CrossRefGoogle Scholar
  5. Berridge MJ (1984) Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 220: 345–360PubMedGoogle Scholar
  6. Biondi M, Pancheri P (1995) Clinical research strategies in psychoimmunology: A review of 46 human research studies (1972-1992). In: Leonard B, Miller K (eds) Stress, the immune system and psychiatry. Wiley, Chichester, pp 85–111Google Scholar
  7. Bornstein RA, Pace P, Rosenberger P, Nasrallah HA, Para MF, Whitacre CC, Fass RJ (1993) Depression and neuropsychological performance in asymptomatic HIV infection. Am J Psychiatry 150: 922–927PubMedGoogle Scholar
  8. Bothwell RA, Eccleston D, Marshall E (1994) Platelet intracellular calcium in patients with recurrent affective disorders. Psychopharmacology 114: 375–381PubMedCrossRefGoogle Scholar
  9. Bredt DS (1995) Molecular characterization of nitric oxide synthase. In: Vincent S (ed) Nitric oxide in the nervous system. Academic, London, pp 1–19CrossRefGoogle Scholar
  10. Caillard V (1985) Treatment of mania using a calcium antagonist—preliminary trial. Neuropsychobiology 14: 23–26PubMedCrossRefGoogle Scholar
  11. Cappel R, Gregoire F, Thiry L, Sprecher S (1978) Antibody and cell-mediated immunity to herpes simplex virus in psychotic depression. J Clin Psychiatry 39: 266–268PubMedGoogle Scholar
  12. Darko DF, Gillin JC, Risch SC, Bulloch K, Golshan S, Tasevska Z, Hamburger RN (1989) Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression. Biol Psychiatry 26: 145–155PubMedCrossRefGoogle Scholar
  13. Darko DF, Irwin MR, Risch SC, Gillin JC (1992) Plasma beta-endorphin and natural killer cell activity in major depression: a preliminary study. Psychiatry Res 43:111– 119Google Scholar
  14. Dose M, Emrich HM, Cording-Tommel C, von Zerssen D (1986) Use of calcium antagonists in mania. Psychoneuroendocrinology 11: 241–243PubMedCrossRefGoogle Scholar
  15. Dubovsky SL, Franks RD, Lifschitz ML, Cohen P (1982) Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 139: 502–504PubMedGoogle Scholar
  16. Dubovsky SL, Franks RD, Allen S, Murphy J (1986) Calcium antagonists in mania: a double-blind study of verapamil. Psychiatry Res 18: 309–320PubMedCrossRefGoogle Scholar
  17. Dubovsky SL, Christiano J, Daniel LC, Franks RD, Murphy J, Adler L, Baker N, Harris A (1989) Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 46: 632–638PubMedCrossRefGoogle Scholar
  18. Dubovsky SL, Murphy J, Thomas M, Rademacher J (1992) Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 149: 118–120PubMedGoogle Scholar
  19. Dunn AJ (1995) Interactions between the nervous system and the immune system: Implications for psychopharmacology. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 719– 731Google Scholar
  20. Eckert A, Gann H, Riemann D, Aldenhoff J, Muller WE (1993) Elevated intracellular calcium levels after 5-HT2 receptor stimulation in platelets of depressed patients. Biol Psychiatry 34: 565–568PubMedCrossRefGoogle Scholar
  21. Evans DL, Folds JD, Petitto JM, Golden RN, Pedersen CA, Corrigan M, Gilmore JH, Silva SG, Quade D, Ozer H (1992) Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression. Arch Gen Psychiatry 49: 388–395Google Scholar
  22. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL (1993) Malignant melanoma, effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50: 681–689PubMedCrossRefGoogle Scholar
  23. Feinstein DL, Galea E, Reis DJ (1994) Suppression of glial iNOS expression by tyrosine kinase inhibitors. Ann NY Acad Sci 738: 325–328PubMedCrossRefGoogle Scholar
  24. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial muscle by acetylcholine. Nature 288: 373–376PubMedCrossRefGoogle Scholar
  25. Garza-Trevino E, Overall JE, Hollister LE (1992) Verapamil versus lithium in acute mania. Am J Psychiatry 149: 121–122PubMedGoogle Scholar
  26. Giannini AJ, Houser WL Jr, Loiselle RH, Giannini MC, Price WA (1984) Antimanic effects of verapamil. Am J Psychiatry 141: 1602–1603PubMedGoogle Scholar
  27. Hoschl C, Kozeny J (1989) Verapamil in affective disorders: a controlled, double-blind study. Biol Psychiatry 25: 128–140PubMedCrossRefGoogle Scholar
  28. Irwin M, Smith TL, Gillin JC (1987a) Low natural killer cytotoxicity in major depression. Life Sci 41: 2127–2133PubMedCrossRefGoogle Scholar
  29. Irwin M, Daniels M, Smith TL, Bloom E, Weiner H (1987b) Impaired natural killer cell activity during bereavement. Brain Behav Immun 1: 98–104PubMedCrossRefGoogle Scholar
  30. Irwin M, Patterson T, Smith TL, Caldwell C, Brown SA, Gillin JC, Grant I (1990) Reduction of immune function in life stress and depression. Biol Psychiatry 27: 22–30PubMedCrossRefGoogle Scholar
  31. Irwin M (1995) Psychoneuroimmunology of depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 983–998Google Scholar
  32. Jankovic BD (1994) Neuroimmunomodulation—from phenomenology to molecular evidence. Ann NY Acad Sci 741: 1–38PubMedGoogle Scholar
  33. Kagaya A, Mikuni M, Muraoka S, Saitoh K, Ogawa T, Shinno H, Yamawaki S, Takahashi K (1993) Homologous desensitization of serotonin 5-HT2 receptor-stimulated intracellular calcium mobilization in C6BU-1 glioma cells via a mechanism involving a calmodulin pathway. J Neurochem 61: 1050–1056PubMedCrossRefGoogle Scholar
  34. Kagaya A, Motohashi N, Kugaya A, Yamaji T, Hayashi T, Okamoto Y, Shinno H, Takebayashi M, Uchitomi Y, Yamawaki S (1995) Cyclic GMP generation mediated by 5-HT-2 receptors via nitric oxide pathway and its effect on the desensitization of 5-HT-2 receptors in C6 glioma cells. J Neural Transm 100: 27–38CrossRefGoogle Scholar
  35. Kagaya A, Uchitomi Y, Kugaya A, Takebayashi M, Nagaoka I, Muraoka M, Yokota N, Yamawaki S (1996) Differential regulation of intracellular signaling systems by sodium fluoride in rat glioma cells. J Neurochem 66: 1483–1488PubMedCrossRefGoogle Scholar
  36. Kagaya A, Uchitomi Y, Takezaki E, Fukue M, Tsukano K, Kugaya A, Minagawa H, Takebayashi M, Zensho H, Oyamada T, Yamawaki S (1997) Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy: a prospective study in Japan. Neuropsychobiology 35: 128–131PubMedCrossRefGoogle Scholar
  37. Kiecolt-Glaser JK, Fisher LD, Ogrocki P, Stout JC, Speicher CE, Glaser R (1987) Marital quality, marital disruption, and immune function. Psychosom Med 49: 13–34PubMedGoogle Scholar
  38. Konopka LM, Cooper R, Crayton JW (1996) Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biol Psychiatry 39: 708–713PubMedCrossRefGoogle Scholar
  39. Kramer MS, Caputo K, DiJohnson L, Mirow A, Sheves P, Sholevar F (1988) Nagative trial of nifedipine in depression. Biol Psychiatry 24: 941–960CrossRefGoogle Scholar
  40. Kronfol Z, Silva J Jr, Greden J (1983) Impaired lymphocyte function in depressed illness. Life Sei 33: 241–247CrossRefGoogle Scholar
  41. Kronfol Z, Nair M, Goodson J, Goel K, Haskett R, Schwartz S (1989) Natural killer cell activity in depressive illness: preliminary report. Biol Psychiatry 26: 753–756PubMedCrossRefGoogle Scholar
  42. Kugaya A, Kagaya A, Uchitomi Y, Motohashi N, Yamawaki S (1995) Inhibition of serotonin-induced Ca2+ mobilization by interleukin-lß in rat C6BU-1 glioma cells. Brain Res 682: 151–156PubMedCrossRefGoogle Scholar
  43. Kusumi I, Koyama T, Yamashita I (1991) Serotonin-stimulated Ca2+ response is increased in the blood platelets of depressed patients. Biol Psychiatry 30: 310–312PubMedCrossRefGoogle Scholar
  44. Kusumi I, Koyama T, Yamashita I (1992) Thrombin-induced platelet calcium mobilization is enhanced in bipolar disorders. Biol Psychiatry 32: 731–734PubMedCrossRefGoogle Scholar
  45. Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA Jr, Evans L, Roenigk HH Jr, Rosen ST (1990) Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82: 203–207PubMedCrossRefGoogle Scholar
  46. Lewis ML, Davis J, Chuang E (1993) Interferon alfa-2a in the treatment of exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 231: 615–618PubMedCrossRefGoogle Scholar
  47. Maes M, Bosmans E, Meitzer HY, Schärpe S, Suy E (1993) Interleukin-lß: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 150:1189– 1193Google Scholar
  48. McDonald EM, Mann AH, Thomas HC (1987) Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant a-interferon in hepatitis-B carriers. Lancet 21: 1175–1178CrossRefGoogle Scholar
  49. Merrill JE, Koyanagi Y, Zack J, Thomas L, Martin F, Chen ISY (1992) Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 66: 2217–2225PubMedGoogle Scholar
  50. Meyers CA, Scheibel RS, Forman AD (1991) Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41: 672–676PubMedGoogle Scholar
  51. Mikuni M, Kagaya A, Takahashi K, Meitzer HY (1992) Serotonin but not norepinephrine-induced calcium mobilization is enhanced in platelets of affective disorders. Psychopharmacology 106: 311–314PubMedCrossRefGoogle Scholar
  52. Murphy S, Grzybicki DM, Simmons ML (1995) Glial cells as nitric oxide sources and targets. In: Vincent S (ed) Nitric oxide in the nervous system. Academic, London, pp 162–190Google Scholar
  53. Okamoto Y, Kagaya A, Shinno H, Motohashi N, Yamawaki S (1995) Serotonin-induced platelet calcium mobilization is enhanced in mania. Life Sei 56: 327–332CrossRefGoogle Scholar
  54. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA (1987) Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 147: 1577–1580PubMedCrossRefGoogle Scholar
  55. Schleifer SJ, Keller SE, Camerino M, Thornton JC, Stein M (1983) Suppression of lymphocyte stimulation following bereavement. JAMA 250: 374–377PubMedCrossRefGoogle Scholar
  56. Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M (1984) Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 41: 484–486PubMedCrossRefGoogle Scholar
  57. Schleifer SJ, Keller SE, Bond RN, Cohen H, Stein M (1989) Major depressive disorder and immunity: role of age, sex, severity, and hospitalization. Arch Gen Psychiatry 46: 81–87PubMedCrossRefGoogle Scholar
  58. Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr (1994) A phase I study of interferon-a2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 169: 981–989PubMedCrossRefGoogle Scholar
  59. Smith MJ, Mouawad R, Vuillemin E, Benhammouda A, Soubrane C, Khayat D (1994) Psychological side effects induced by interleukin-2/a interferon treatment. Psycho–Oncol 3: 289–298CrossRefGoogle Scholar
  60. Tan CH, Martin AJ, Ermias S, Patricia AL, Charles LB (1990) Effects of lithium on platetet ionic intracellular calcium concentration in patients with bipolar (manic–depressive) disorder and healthy controls. Life Sei 46: 1175–1180CrossRefGoogle Scholar
  61. Thomas MA, Ibanez HE (1993) Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization. Am J Ophthalmol 115: 563–568PubMedGoogle Scholar
  62. Ur E, White PD, Grossman A (1992) Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci 241: 317–322PubMedCrossRefGoogle Scholar
  63. Urch A, Muller C, Aschauer H, Resch F, Zielinski CC (1988) Lytic effector cell function in schizophrenia and depression. J Neuroimmunol 18: 291–301PubMedCrossRefGoogle Scholar
  64. Wachtel H (1990) The second-messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry 23: 27–32PubMedCrossRefGoogle Scholar
  65. Waiden J, Frintze J, van Calker D, Berger M, Grunze H (1995) A calcium antagonist for the treatment of depressive episode: single case reports. J Psychiat Res 29: 71–76CrossRefGoogle Scholar
  66. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H (1994) Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 35: 42–47PubMedCrossRefGoogle Scholar
  67. Yamawaki S, Sugihara J, Kato T, Hayakawa H, Shimizu M (1990) 5-HT2 receptor–mediated Ca2+ increase in platelets of bipolar disorder. Presented at the 17th Congress of CINP. Abstracts, p 29Google Scholar
  68. Yamawaki S, Kagaya A, Hayakawa H, Okamoto Y, Kugaya A, Takebayashi M, Muraoka M, Uchitomi Y (1995) Pathophysiology of affective disroders: serotonin receptor function and intracellular calcium signaling. In: Takada A, Curzon G (eds) Serotonin in the central nervous system and periphery. Elsevier, Amsterdam, pp 31– 39Google Scholar
  69. Yamawaki S, Kagaya A, Okamoto Y, Uchitomi Y, Shimizu M, Nishida A (1996a) Role of intracellular calcium mechanisms in the pathophysiology of affective disorders. In: Shibuya T (ed) International academy for biomedical and drug research, vol 11: Preclinical and clinical strategies for the treatment of neurodegenerative, cerebrovascular and mental disorders. Karger, Basel, pp 106–115Google Scholar
  70. Yamawaki S, Kagaya A, Okamoto Y, Shimizu M, Nishida A, Uchitomi Y (1996b) Enhanced calcium response to serotonin in platelets from patients with affective disorders. J Psychiatr Neurosci 21: 321–324Google Scholar

Copyright information

© Springer-Verlag Tokyo 1998

Authors and Affiliations

  • Ariyuki Kagaya
    • 1
  • Shigeto Yamawaki
    • 1
  1. 1.Department of Psychiatry and NeurosciencesHiroshima University School of MedicineMinami-ku, Hiroshima 734Japan

Personalised recommendations